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Abstract b-Secretase or b-site amyloid precursor protein
cleaving enzyme (BACE-1) is a membrane-associated
aspartyl protease that catalyzes the first step in the formation
of amyloid b plaques responsible for Alzheimer’s disease
(AD). b-Secretase has been considered as a striking thera-
peutic target for AD. Recently, several attempts have been
focused on the development of inhibitors of this key protease.
Among small molecules, scaffolds based on isophthalamide
derivatives have been reported as potent non-peptidic BACE-
1 inhibitors. In the present study, interactions of a 5-(N-
methylmethan-4-ylsulfonamido) isophthalamide-based scaf-
foldwithBACE-1 active site residues have been evaluated via
the functional B3LYP in association with split valence basis
set using polarization functions (Def2-SVP). The complex
ligand–receptor system includingN1-(4-(cyclopropylamino)-
3-hydroxy-1-phenylbutan-2-yl)-5-(N-methylmethan-4-ylsul-
fonamido)-N3(1-phenylethyl) isophthalamide (5HA) and 18
amino acids constructing BACE-1 active site exhibited
H-bonds, p–p stacking, and Van der Waals interactions
associated with total binding energy of -268.34 kcal/mol at
B3LYP/Def2-SVP level. The outcomes of conformational
analysis postulated that the studied isophthalamide-based
structure might not necessarily interact with the active site of
BACE-1 in its optimum geometric conformation.
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Introduction
Alois Alzheimer was the first person who discovered
Alzheimer’s disease (AD) in 1907 (Querfurth and LaFerla,
2010). This neuronal disease is associated with a loss of
memory and finally leads to the brain dementia (McKhann
et al., 1984). The amyloid cascade hypothesis proposes that
most patients bearing AD are involved with aggregation of
amyloid b40 and 42 (Ab40 and Ab42) oligopeptides in
their brains (Selkoe, 2008). Ab40 and Ab42 are generated
from a large trans-membrane protein, amyloid precursor
protein (APP), by the proteolytic action of b-site APP
cleaving enzyme (BACE-1) in an amyloidogenic pathway
(Kurz and Perneczky, 2011). In hydrophilic media hydro-
phobic Ab oligopeptides are converted to neurotoxic
polymeric plaques. The agglomeration of these neurotoxic
plaques causes neuronal dystrophy and inflammation end-
ing up to neuronal dementia (Selkoe, 2000).
BACE-1 is a type I membrane-associated aspartyl pro-
tease (Hevener et al., 2009). This enzyme has been con-
sidered to be an attractive therapeutic target in AD due to
some advantages; the enzyme catalyzes the first step in Ab
production, it is mainly expressed in brain, and finally it is
selective in its proteolytic activity (Vassar, 2002; Roberds
et al., 2001; Luo et al., 2001). Regarding this, development
of specific inhibitors of this key protease has been con-
sidered as a major therapeutic tool in AD treatment. Many
research groups have focused on development of b-secre-
tase inhibitors (Ghosh et al., 2000; Hamada et al., 2008;
Manzenrieder et al., 2007; Hanessian et al., 2005; Xiao
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